SMITHKLINE BEECHAM HAVRIX IS FIRST HEPATITIS A VACCINE APPROVED IN THE U.S. FOLLOWING FEB. 22 CLEARANCE; EFFICACY RATE OF 84% SHOWN IN 40,000-PATIENT STUDY IN CHILDREN
Executive Summary
SmithKline Beecham's inactivated hepatitis A vaccine Havrix will be the first hepatitis A vaccine marketed in the U.S. following an FDA green light for marketing on Feb. 22.